Evidence map›Paper›PMID 40577361›Full record

ArticlePloS one2025

Lipoprotein(a) levels in a sample of 115,197 subjects from the largest Brazilian private laboratory.

Maria Helane Costa Gurgel Castelo, Isac de Castro, Priscila Raupp-da-Rosa, Patrícia Cristina Grenzi, Eduardo Gomes Lima, Andreza Almeida Senerchia, Érica Ferreira, Flavia Paiva Proença Lobo Lopes

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Helane Costa Gurgel CasteloClinical Pathology Department, DASA, São Paulo, SP, Brazil.ORCID 0000-0003-3816-5612
Isac de CastroClinical Pathology Department, DASA, São Paulo, SP, Brazil.
Priscila Raupp-da-RosaEvidence Generation, Novartis Biociências S.A, São Paulo, SP, Brazil.ORCID 0000-0002-5570-1475
Patrícia Cristina GrenziExternal Scientific Engagement, Alexion Pharmaceuticals, São Paulo, SP, Brazil.
Eduardo Gomes LimaClinical Research, DASA, São Paulo, SP, Brazil.
Andreza Almeida SenerchiaClinical Research, DASA, São Paulo, SP, Brazil.
Érica FerreiraStudy & Site Operations (SSO) Study Start-Up, Novartis Biociências S.A., São Paulo, SP, Brazil.
Flavia Paiva Proença Lobo LopesResearch, Education and Innovation Department, DASA, São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) (Lp(a)) is an independent risk factor for atherosclerotic disease and is increasingly being incorporated into clinical algorithms of cardiovascular risk prediction. However, the epidemiology of Lp(a) in Brazil remains unknown. The objective of this study was to describe the distribution of Lp(a) levels and its association with laboratory parameters and clinical characteristics in a population of subjects submitted to blood tests in a private laboratory. Methods involved assessing Lp(a) levels from 115,197 subjects in a nationwide database from one Brazilian private laboratory, with Lp(a) measured using a nephelometric assay and expressed in mg/dL. Results showed that among the 115,197 subjects, the median age was 44 years. Women composed 61% of the sample and displayed higher Lp(a) levels in comparison to men (13.90 vs 11.58 mg/dL, p < 0.001). The distribution of Lp(a) levels was skewed rightward, as 70% of the individuals showed levels < 30 mg/dL, and 18% had levels higher than 50 mg/dL. The presence of criteria for diabetes, metabolic syndrome, and levels of HDL-cholesterol and triglycerides showed no correlation with Lp(a) levels. Additionally, there was no significant association between Lp(a) levels in individuals with and without criteria for diabetes and metabolic syndrome. In conclusion, this study represents the largest descriptive analysis of Lp (a) in Brazil, encompassing individuals with a wide age range and geographical distribution. This data contributes to the generation of high-quality evidence needed for improving cardiovascular risk assessment in clinical care settings.

Indexed as

Lipoprotein(a)AdultAgedBrazilCardiovascular DiseasesCholesterol, HDLFemaleHumansLaboratoriesMaleMiddle AgedRisk FactorsTriglyceridesYoung AdultCholesterol, HDLLipoprotein(a)Triglycerides

Identifiers

PMID40577361
PMCPMC12204575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.